Capricor Therapeutics, Inc.

Five-year HOPE 2 open label extension data backs up Phase 3 HOPE 3 results with durable functional and cardiac outcomes, providing a compelling data package for the FDA advisory committee meeting on July 29, 2026. Analysts project $245.5 million in revenue and $109.6 million in earnings by 2029 upon approval.

Capricor currently generates no revenue and has been diluting shareholders, meaning an adverse FDA decision or further delay could leave the company with elevated operational commitments and no path to near-term cash generation. Pessimistic analysts model only $114.5 million in revenue and $32.5 million in earnings by 2029.

With a consensus analyst price target of $53.60 against a last close of $19.12, Capricor shares trade roughly 64% below consensus. Simply Wall St estimates the stock trades 92.1% below its fair value, and a separate model pegs fair value at $54.67, implying roughly 144% upside from current levels.

Technical indicators paint a deeply negative picture, with sell signals from both short- and long-term moving averages and a falling MACD. The stock has declined 26.6% over the past month and 34.65% since January 1, suggesting that weak momentum may undermine the large gap between price and analyst targets.

Capricor's new conditional lease agreement for expanded San Diego headquarters signals management's confidence in a positive Deramiocel FDA outcome, and the company reports $145 million in cash alongside active commercial launch preparations, demonstrating institutional readiness for a post-approval ramp.

The lease structure ties Capricor's entire future operating footprint to a single FDA milestone, concentrating both opportunity and risk around one regulatory decision. Analyst price targets have already been cut by $5 to $38 following the removal of an expected $80 million milestone payment, highlighting fragility in the commercial outlook.